Share on StockTwits

ZIOPHARM Oncology (NASDAQ:ZIOP) posted its quarterly earnings results on Thursday. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.17) by $0.11, Analyst Ratings Network.com reports. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $7.50 million. During the same quarter last year, the company posted ($0.22) earnings per share. ZIOPHARM Oncology’s revenue was up .0% compared to the same quarter last year.

ZIOPHARM Oncology (NASDAQ:ZIOP) traded down 4.33% on Thursday, hitting $3.09. The stock had a trading volume of 419,338 shares. ZIOPHARM Oncology has a 52-week low of $2.75 and a 52-week high of $5.58. The stock’s 50-day moving average is $3.56 and its 200-day moving average is $3.91. The company’s market cap is $309.9 million.

ZIOPHARM Oncology, Inc, is a biotechnology company. The Company employs gene expression and control technology to deliver deoxyribonucleic acid (NASDAQ:ZIOP) for the treatment of cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.